Preclinical study identifies ascites targets and tests E8 nanobody efficacy

A preclinical study conducted in Singapore identified PAI-1 and S100A10 as key drivers of peritoneal metastases associated with ascites. The study demonstrated that the PAI-1-targeting nanobody E8 suppressed tumor growth in cell cultures, mouse models, and human tissue samples, though clinical benefits in patients have not yet been tested.

Originally published by gnews